Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR).
Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards